A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

Abstract

Objectives. Gemcitabine and carboplatin each have demonstrated effectiveness without increased neurotoxicity in pretreated patients with ovarian cancer. We evaluated the efficacy and safety of gemcitabine plus carboplatin in patients with recurrent ovarian cancer in a multicenter phase II study.